Ads
related to: pompe disease new treatment guidelines for hyperlipidemia patients mayo clinic
Search results
Results From The WOW.Com Content Network
In August 2006, Health Canada approved Myozyme for the treatment of Pompe disease. In June 2007, the Canadian Common Drug Review issued its recommendations regarding public funding for Myozyme therapy. Their recommendation was to provide funding to treat a tiny subset of Pompe patients (Infants less one year of age with cardiomyopathy). [10]
Joannes Cassianus Pompe (9 September 1901, Utrecht – 15 April 1945, Sint Pancras) was a Dutch pathologist. [1] In 1932, he characterized the condition now known as Glycogen storage disease type II .
Feb. 16—With those New Year's resolutions six weeks behind us, some people may have reverted to less healthy ways of eating. Heart Month is a great time to remind yourself why a healthy diet is ...
Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. [1] It is a form of hyperlipidemia (high levels of lipids in the blood), hyperlipoproteinemia (high levels of lipoproteins in the blood), and dyslipidemia (any abnormalities of lipid and lipoprotein levels in the blood).
Hyperlipidemia is abnormally high levels of any or all lipids (e.g. fats, triglycerides, cholesterol, phospholipids) or lipoproteins in the blood. [2] The term hyperlipidemia refers to the laboratory finding itself and is also used as an umbrella term covering any of various acquired or genetic disorders that result in that finding. [3]
Dyslipidemia is a risk factor for the development of atherosclerotic cardiovascular diseases, [1] which include coronary artery disease, cerebrovascular disease, and peripheral artery disease. [1] Although dyslipidemia is a risk factor for cardiovascular disease , abnormal levels do not mean that lipid lowering agents need to be started. [ 2 ]
Ads
related to: pompe disease new treatment guidelines for hyperlipidemia patients mayo clinic